Pregnancy

SKYLARK Trial Unveils Promising Oral Therapy for Postpartum Depression

The SKYLARK Study, conducted by The Feinstein Institutes for Medical Research at Northwell Health, has shown promising results in treating postpartum depression (PPD). Led by Dr. Kristina M. Deligiannidis, the trial evaluated the efficacy of an investigational oral neuroactive steroid, zuranolone (50mg). The findings suggest zuranolone could become the first oral, at-home therapy approved by the FDA for PPD. The study included…

Google Teams Up with Cypriot Femtech Startup Soula to Advance Pregnancy Care

Google has partnered with Soula, a Cyprus-based femtech startup, to enhance the support services available for pregnancy and parenting. This collaboration centers on Soula’s application of Google’s medical language model, Med-PaLM, to its AI-assistant. Med-PaLM is a highly sophisticated language model specifically designed to handle medical inquiries. By integrating this technology into its platform, Soula plans to offer comprehensive and reliable support…

Sonio Raises $14M in Series A Funding for Its AI-based Prenatal Screening and Diagnostics Platform

Sonio, a French medtech company specializing in improving the health of pregnant individuals and children, has raised $14M in Series A funding led by Cross Border Impact Ventures and the Elaia funds. The funding follows the initial commitment of the EIC Fund (European Innovation Council) in December 2022 and will play a pivotal role in advancing Sonio’s SaaS solution, expanding its presence…

Indonesia: SoftBank-backed Digital Health Platform Alodokter Acquires Pregnancy App Diary Bunda

Alodokter, a prominent digital health platform in Indonesia backed by SoftBank, has taken a step to enhance its services with the acquisition of Diary Bunda, a popular pregnancy tracking app. The app was acquired from Marubeni Corporation, a Japanese company. The financial details of the transaction have not been disclosed. Diary Bunda has gained a loyal following among Indonesian mothers, offering personalized…

FDA Approves Thermo Fisher’s Immunoassays for Risk Assessment of Preeclampsia

Thermo Fisher Scientific has announced that its novel immunoassays, the Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR biomarkers, have received clearance from the U.S. Food and Drug Administration (FDA). These breakthrough biomarkers are the first and only immunoassays to be cleared for the risk assessment and clinical management of preeclampsia, a severe complication during pregnancy. Preeclampsia is a dangerous…

Janssen’s Nipocalimab Shows Promise for Treatment of High-Risk Pregnancies with Severe HDFN in Phase 2 Trial

Nipocalimab, an investigational treatment developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, has demonstrated promising outcomes in pregnant individuals at high risk of early-onset severe haemolytic disease of the foetus and newborn (HDFN). HDFN is a rare blood disorder which occurs in between 3 and 80 out of every 100.000 pregnancies and can be fatal. The Phase 2 clinical trial…

AI-powered Health Care Model Proves Successful in Reducing Preterm Births and NICU Admissions

In a leap forward for maternal health, Molina Healthcare, in partnership with Lucina Analytics and Progeny Health, recently disclosed the promising results of their obstetrics health care model. This model, which incorporates artificial intelligence (AI), impacts the full cycle of obstetrical care, from early pregnancy detection to post-NICU community-based care management. Molina Healthcare, a FORTUNE 500 company, provides managed healthcare services under…